Chemical formula: C₂₁H₄₆NO₄P Molecular mass: 407.576 g/mol PubChem compound: 3599
There are no adequate data from the use of miltefosine in pregnant women. Studies in animals have shown reproductive toxicity.
Miltefosine is contraindicated in pregnancy. Women of childbearing potential have to use effective contraception during and up to 5 months aftertreatment. Vomiting and diarrhea are very common side effects of therapy with miltefosine and can compromise the efficacy of oral contraception. The patient must be informed by her physician, accordingly. If necessary,suitable alternative methods of contraception must be used.
During pregnancy, visceral leishmaniasis may be life-threatening for the mother and may result in adverse fetal outcomes, including spontaneous abortion, congenital disease due to vertical transmission, small for gestational age newborn, and severe anemia. During pregnancy, cutaneous leishmaniasis may manifest with larger and atypical appearing lesions and may be associated with increased risk for adverse fetal outcomes, including preterm births and still births.
The patient has to be advised to immediately contact her physician for pregnancy testing as soon as there is any suspicion of pregnancy. If the test is positive, the physician and patient must discuss the risks associated with this pregnancy.
It is not known whether miltefosine is excreted in the milk. Miltefosine must not be used during lactation; Breastfeeding should be avoided for 5 months after miltefosine therapy.
Studies in ratsrevealed testicular atrophies and an impairment of fertility after the treatment with miltefosine. These results were reversible after a recovery period of 10 weeks. Data with regard to the impact of miltefosine to the fertility in men are not available.
Advise women and men of the animal fertility findings, and that the potential for impaired fertility with miltefosine therapy has not been adequately evaluated.
Miltefosine may cause undesirable effects such as nausea which may impair the patient’s ability to concentrate and react properly. In such cases patients should refrain from driving cars and using machines.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
